Chemotherapy can affect several body systems at once, and the likelihood of a symptom depends on the drug, regimen, cancer type, and time since treatment. The statistics below describe reported rates for specific studies, treatment combinations, and patient groups; they are not a prediction for any one person.
Contents
- Neuropathy over time
- Fatigue and daily functioning
- Nausea and vomiting
- Mouth symptoms and digestive effects
- Blood-count complications
- Oxaliplatin and platinum-related neuropathy
- Adverse events in a docetaxel regimen
Neuropathy over time
Chemotherapy-induced peripheral neuropathy (CIPN) can cause tingling, numbness, burning, pain, or sensitivity in the hands and feet. Its reported prevalence was highest soon after chemotherapy and lower at later follow-up in a systematic review and meta-analysis titled Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
| Measurement point after chemotherapy | Reported CIPN prevalence |
|---|---|
| First month | 68.1% |
| Three months | 60.0% |
| Six months or more | 30.0% |
These figures describe prevalence at different follow-up points, not the percentage of the same symptoms that necessarily disappeared in every patient. The review’s results still show why caregivers may need to ask about sensation and balance beyond the first treatment period. A symptom that is less common at six months can remain important for the people who continue to experience it.
The same review found that neuropathy was not limited to one medication. In a source summarized by an FDA oxaliplatin label, oxaliplatin-associated neuropathy occurred in 48% of study patients. A review titled Oxaliplatin-Induced Neuropathy in Colorectal Cancer reported that grade 2 or worse oxaliplatin-induced neuropathy occurs in approximately 40% to 50% of patients, while grade 3 neuropathy occurs in approximately 10% to 20%.
Fatigue and daily functioning
Fatigue can affect activity, concentration, sleep, and the ability to manage ordinary tasks. A systematic review and meta-analysis titled Prevalence of cancer-related fatigue based on severity: a systematic review and meta-analysis reported severe cancer-related fatigue in 33.1% of patients receiving chemotherapy.
The same analysis reported severe fatigue at several treatment stages:
- 15.9% before treatment
- 33.8% during ongoing treatment
- 24.1% after treatment
The study also found variation by tumor group. Severe fatigue was reported in 39.7% of people with brain tumors and 3.9% of people with gynecologic tumors. These are group-level prevalence estimates, so they should not be used to infer an individual’s expected fatigue. They do show why caregiver support may need to change as treatment begins, continues, and ends.
Nausea and vomiting
Platinum-based chemotherapy is associated with substantial gastrointestinal symptom burdens. In Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis, nausea was reported in 52% of patients and vomiting in 37%.
Delayed symptoms can remain relevant after the infusion or treatment visit. In Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone, delayed chemotherapy-induced nausea and vomiting was reported by 43% to 57% of patients. Acute chemotherapy-induced nausea and vomiting total control was achieved in 78% of patients in that trial.
Antiemetic regimen results can be expressed as odds ratios rather than percentages. In Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis, aprepitant triple therapy improved overall complete response with an odds ratio of 1.88. The odds ratio was 1.96 for acute complete response and 1.96 for delayed complete response. An odds ratio compares the odds of an outcome between treatment groups; it is not the same as a percentage-point increase.
For caregivers, the timing of symptoms matters as much as the symptom label. Nausea or vomiting may occur acutely, later, or in both periods. The reported delayed range is a reminder that support needs can continue after a patient leaves the treatment center.
Mouth symptoms and digestive effects
Oral mucositis is inflammation and injury of the mouth lining. In Oral Mucositis in Adult Cancer Patients Undergoing Chemotherapy: Six-Month On-Treatment Follow-Up, oral mucositis had a six-month cumulative incidence of 53.13% in one chemotherapy cohort. Oral ulceration in that cohort had a six-month cumulative incidence of 43.75%.
The same follow-up paper cited a recent meta-analysis reporting 42.9% prevalence among patients treated with chemotherapy alone. Because the cohort’s cumulative incidence and the cited meta-analysis prevalence use different measures and evidence bases, they should not be treated as interchangeable estimates.
Digestive symptoms also varied by regimen. In an FDA docetaxel/capecitabine label summary, the docetaxel-plus-capecitabine regimen was associated with diarrhea in 67% of patients, nausea in 45%, vomiting in 35%, constipation in 20%, and abdominal pain in 30%. Stomatitis occurred in 67% of patients in the same combination arm.
Those figures come from a specific regimen and should not be generalized to all chemotherapy. They can nevertheless help caregivers recognize why hydration, meal planning, mouth care, and communication with the oncology team may become recurring parts of support.
Blood-count complications
Chemotherapy can affect blood cells, but the reported risk depends on cancer type, regimen, and severity grade. In The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies, the three-month cumulative incidence after chemotherapy reached 13.3% for grade 3 thrombocytopenia in patients with melanoma and 5.0% for grade 4 thrombocytopenia.
The same source reported that the three-month risk of grade 3 and grade 4 thrombocytopenia was 5% or less in common lung and colorectal cancers. These results are not a universal rate for every patient receiving chemotherapy; they compare particular cancer populations and severity categories.
The FDA docetaxel/capecitabine label summary reported the following blood-related events in the combination arm: neutropenia, 26%; anemia, 12%; leukopenia, 6%; and thrombocytopenia, 5%. The percentages describe reported events in that safety table and do not indicate that every event was equally severe.
Oxaliplatin and platinum-related neuropathy
Platinum drugs show different reported neuropathy ranges. In Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis, neuropathic symptoms were reported in 49% to 100% of cisplatin cases and 13% to 42% of carboplatin cases. These are ranges across reported cases, not a head-to-head estimate for a single standardized trial.
Oxaliplatin can also produce acute, cold-triggered symptoms. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review reported cold-induced acute oxaliplatin neuropathic symptoms in 65% to 98% of patients during and immediately after the first treatment.
Longer-term symptoms have also been reported. In Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin, paclitaxel- and docetaxel-related CIPN symptoms were still present in 42% of patients two years after docetaxel therapy. The same source reported symptoms still present in 84% of patients two years after oxaliplatin therapy. The wording of these findings connects the first percentage with docetaxel therapy and the second with oxaliplatin therapy; they should not be read as a general two-year rate for all chemotherapy.
Adverse events in a docetaxel regimen
The FDA docetaxel/capecitabine label summary provides a compact view of how adverse-event rates differed between a combination arm and a docetaxel comparator arm.
| Event | Docetaxel + capecitabine | Docetaxel comparator |
|---|---|---|
| Diarrhea | 67% | 48% |
| Stomatitis | 67% | 43% |
| Nausea | 45% | 36% |
| Vomiting | 35% | 24% |
| Constipation | 20% | 18% |
| Abdominal pain | 30% | 24% |
The combination arm’s safety table also reported hand-foot syndrome in 63% of patients, alopecia in 41%, nail disorder in 14%, rash in 9%, dermatitis in 8%, and onycholysis in 5%. These skin, hair, and nail effects can add practical care needs alongside gastrointestinal symptoms.
Dose changes were common in this particular treatment setting: the FDA label summary reported that docetaxel plus capecitabine required dose reductions in 65% of patients because of adverse reactions. It also reported that 76.5% of patients in the trial had at least one adverse event. A dose reduction is a treatment-management outcome, not proof that every adverse event was severe, and the figures apply to the summarized trial rather than chemotherapy in general.
For caregiver planning, the overall pattern is important: symptoms may involve sensation, energy, digestion, the mouth, blood counts, skin, hair, and nails, and they may persist or emerge at different points. The most useful response is to track what occurs, when it occurs, and which treatment or follow-up period it relates to, then share that record with the oncology team.